PremiumCompany AnnouncementsAntengene’s XPOVIO® Gains Approval in Indonesia for Multiple Indications Antengene Expands AI Investment to Boost T-Cell Engager Development Antengene’s XPOVIO Gains Taiwan Health Insurance Approval PremiumCompany AnnouncementsAntengene Optimizes Costs, Reduces Losses in 2024 H1 Antengene’s XPOVIO® Wins Approval in Malaysia Antengene Schedules Board Meeting for Financial Update PremiumCompany AnnouncementsAntengene Shareholders Approve Key Resolutions